World News

Both programmes will combine SOPHiA GENETICS’ decentralised clinical trial assay capabilities with AstraZeneca’s oncology therapies.

SMT’s adoption of Teamcenter is intended to improve visibility into product development activities while helping the company manage the documentation and controls required in the highly regulated medical device industry.

The company has launched Invenia Automated Breast Ultrasound (ABUS) Prime and ABUS StreamVue, which target different stages of the breast imaging workflow.

The Phase 1 study forms part of an expanded collaboration between Moderna and the Coalition for Epidemic Preparedness Innovations (CEPI).

Under the definitive agreement, KKR will acquire all outstanding shares of Integer Holdings for US$127 per share in cash.

The transaction is subject to customary closing conditions, including regulatory approvals, and is expected to close in the fourth quarter of 2026.

The decision follows the failure of the phase 3 Lagoon trial, which did not meet its primary endpoint of overall survival.

The test could also help clinicians identify patients who are unlikely to benefit from immunotherapy before treatment begins, potentially allowing them to consider alternative therapies sooner.

DeepHealth Breast Ultrasound automates several stages of breast ultrasound examinations, including lesion detection, characterisation and reporting.

CereVasc designed the facility to meet the company’s expected operational needs as it advances the eShunt System towards potential commercialisation.